Core Insights - OS Therapies Inc. celebrates the passage of the Mikaela Naylon Give Kids A Chance Act, which aims to enhance research and therapeutic access for pediatric cancer patients, particularly those with osteosarcoma [1][5] - Pediatric cancers are the leading cause of disease-based death among children in the U.S., highlighting the urgent need for innovative treatments [2] - The reauthorization of the Rare Pediatric Disease Designation (RPDD) Priority Review Voucher (PRV) program allows OS Therapies to extend its timeline for submitting a Biologics License Application (BLA) for its lead product, OST-HER2, until September 30, 2029 [3][6] Company Developments - OS Therapies is focused on developing listeria-based cancer immunotherapies, with OST-HER2 being its lead asset, which has shown positive results in clinical trials for recurrent pulmonary metastatic osteosarcoma [7] - The company is also evaluating other pipeline products for potential PRV opportunities and benefits under the FDA Platform Technology Designation Program [4] - OST-HER2 has received multiple designations from regulatory bodies, including Orphan Disease Designation and Fast Track Designation, which facilitate its development and potential market entry [6][7] Future Prospects - The company is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced drug delivery [8] - OS Therapies is committed to transforming the lives of children and teens affected by osteosarcoma and other rare cancers, building on the legacy of patients like Mikaela Naylon [5]